PTC Therapeutics PTCT
$56.42 −$1.91 (-3.27%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $56.99 +1.01%
Open$58.78
Prev close$58.33
Day range$56.18 – $58.96
Volume952.6K
Market cap$4.71B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$357.81M+69.6% YoY
Operating profit$25.11M+620.0% YoY
Net profit-$51.69M-425.2% YoY
Diluted EPS-$0.62-410.0% YoY
Free cash flow-$31.33M+90.3% YoY
Operating cash flow-$25.31M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin93.2%
Operating margin12.0%
Net margin-9.2%
Return on assets-3.6%
Current ratio3.27
Liabilities / assets106.0%
Cash & investments$2.13B
Total debt$621.82M
Net cash (debt)$1.51B
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $357.81M | $360.52M | $272.55M | $1.73B | $164.68M |
| Total Operating Revenue | $357.81M | $360.52M | $272.55M | $1.73B | $164.68M |
| Cost of Revenue | $23.66M | $19.92M | $28.03M | $47.01M | $6.95M |
| Gross Profit | $334.14M | $340.60M | $244.52M | $1.68B | $157.73M |
| Operating Expense | $309.03M | $191.62M | $198.64M | $827.13M | $239.35M |
| Selling and Admin Expenses | $80.08M | $80.63M | $86.18M | $347.14M | $96.87M |
| Research & Development | $216.35M | $99.15M | $100.87M | $455.25M | $133.13M |
| Depreciation & Amortization & Depletion | $12.60M | $11.84M | $11.58M | $24.74M | $9.35M |
| -Depreciation & Amortization | $12.60M | $11.84M | $11.58M | $24.74M | $9.35M |
| Operating Profit | $25.11M | $148.98M | $45.89M | $856.51M | -$81.62M |
| Net Non-Operating Interest Income (Expense) | -$45.87M | -$48.48M | -$49.03M | -$152.23M | -$55.19M |
| Non-Operating Interest Expense | $45.87M | $48.48M | $49.03M | $152.23M | $55.19M |
| Other Income (Expense) | -$20.34M | -$2.95M | $682,000.00 | -$7.66M | -$2.27M |
| Special Income (Charges) | -$19.26M | $0.00 | -$927,000.00 | $10.43M | $10.28M |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | $0.00 | $0.00 | -$800,000.00 | $0.00 |
| -Less:Impairment of Capital Assets | $0.00 | $0.00 | $927,000.00 | -$9.63M | -$10.28M |
| -Less:Other Special Charges | $19.26M | – | – | – | – |
| Other Non-Operating Income (Expenses) | -$1.07M | -$2.95M | $1.61M | -$18.09M | -$12.55M |
| Pretax Profit | -$41.09M | $97.55M | -$2.46M | $696.62M | -$139.08M |
| Tax | $10.61M | $14.05M | $347,000.00 | $13.98M | -$4.12M |
| Net Profit | -$51.69M | $83.50M | -$2.81M | $682.64M | -$134.97M |
| Profit from Continuing Operations | -$51.69M | $83.50M | -$2.81M | $682.64M | -$134.97M |
| Net Income to Parent Company | -$51.69M | $83.50M | -$2.81M | $682.64M | -$134.97M |
| Net Income to Common Stockholders | -$51.69M | $83.50M | -$2.81M | $682.64M | -$134.97M |
| Basic EPS | -$0.62 | $1.01 | -$0.03 | $8.58 | -$1.67 |
| Diluted EPS | -$0.62 | $0.92 | -$0.03 | $8.58 | -$1.67 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $3.21B | $3.25B | $2.87B | $2.90B | $2.90B |
| Total Current Assets | $2.54B | $2.62B | $2.25B | $2.27B | $2.27B |
| Cash and Cash Equivalents & Short-Term Investments | $2.13B | $2.23B | $1.89B | $1.95B | $1.95B |
| -Cash and Cash Equivalents | $508.89M | $1.05B | $833.99M | $984.65M | $984.65M |
| -Short Term Investments | $1.62B | $1.18B | $1.06B | $960.72M | $960.72M |
| Receivables | $238.07M | $239.04M | $219.92M | $181.62M | $181.62M |
| -Accounts Receivable | $238.07M | $239.04M | $219.92M | $181.62M | $181.62M |
| Inventory | $109.33M | $91.35M | $75.57M | $79.65M | $79.65M |
| Other Current Assets | $62.47M | $57.88M | $66.05M | $67.31M | $67.31M |
| Total Non-Current Assets | $669.93M | $633.12M | $615.10M | $624.82M | $624.82M |
| Net PPE | $122.28M | $126.27M | $129.43M | $135.42M | $135.42M |
| -Gross PPE | $122.28M | $126.27M | $129.43M | $182.42M | $182.42M |
| Goodwill and Other Intangible Assets | $526.03M | $485.27M | $463.03M | $471.09M | $471.09M |
| -Goodwill | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M |
| -Other Intangible Assets | $443.69M | $402.93M | $380.68M | $388.75M | $388.75M |
| Other Non-Current Assets | $21.63M | $21.58M | $22.65M | $18.30M | $18.30M |
| Total Liabilities | $3.40B | $3.42B | $3.05B | $3.10B | $3.10B |
| Total Current Liabilities | $776.08M | $771.07M | $923.60M | $968.43M | $968.43M |
| Payables | $121.59M | $70.45M | $25.48M | $50.58M | $50.58M |
| -Accounts Payable | $41.59M | $40.45M | $25.48M | $45.49M | $45.49M |
| -Total Tax Payable | $0.00 | $0.00 | $0.00 | $4.68M | $4.68M |
| -Other Payable | $80.00M | $30.00M | – | $416,000.00 | $416,000.00 |
| Current Accrued Expenses | $170.49M | $152.93M | $127.60M | $127.76M | $127.76M |
| Short-Term Debt and Capital Lease Obligation | $14.21M | $73.42M | $305.02M | $585.12M | $585.12M |
| -Current Capital Lease Obligation | $14.21M | $17.97M | $18.08M | $15.48M | $15.48M |
| Current Provisions | $100.32M | $119.56M | $126.13M | $129.20M | $129.20M |
| Current Deferred Liabilities | $1.98M | $1.19M | $498,000.00 | $2.04M | $2.04M |
| Other Current Liabilities | $319.08M | $314.22M | $305.04M | – | – |
| Total Non-Current Liabilities | $2.62B | $2.64B | $2.13B | $2.14B | $2.14B |
| Long Term Debt and Capital Lease Obligation | $621.82M | $623.05M | $90.07M | $2.12B | $2.12B |
| -Long Term Debt | $536.27M | $535.52M | – | $2.03B | $2.03B |
| -Long Term Capital Lease Obligation | $85.55M | $87.53M | $90.07M | $96.58M | $96.58M |
| Other Non-Current Liabilities | $2.00B | $2.02B | $2.04B | $13.70M | $13.70M |
| Total Equity | -$191.21M | -$165.36M | -$180.47M | -$205.31M | -$205.31M |
| Stockholders' Equity | -$191.21M | -$165.36M | -$180.47M | -$205.31M | -$205.31M |
| Capital Stock | $82,000.00 | $82,000.00 | $81,000.00 | $80,000.00 | $80,000.00 |
| -Common Stock | $82,000.00 | $82,000.00 | $81,000.00 | $80,000.00 | $80,000.00 |
| Additional Paid-In Capital | $2.74B | $2.71B | $2.78B | $2.75B | $2.75B |
| Retained Earnings | -$2.94B | -$2.88B | -$2.97B | -$2.96B | -$2.96B |
| Gains/Losses Not Affecting Retained Earnings | $2.55M | $6.02M | $8.47M | $10.50M | $10.50M |
| -Current Debt | – | $55.45M | $286.94M | $569.63M | $569.63M |
| -Accumulated Depreciation | – | – | – | -$46.99M | -$46.99M |
| Long Term Accounts Payable and Other Payables | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$25.31M | $129.11M | -$59.04M | $711.20M | -$34.27M |
| Net cash flow from continuing operations | -$25.31M | $129.11M | -$59.04M | $711.20M | -$34.27M |
| Net Income from Continuing Operations | -$51.69M | $83.50M | -$2.81M | $682.64M | -$134.97M |
| Gain/Loss from Continuing Operations | $18.52M | $1.35M | $40,000.00 | $10.75M | $5.82M |
| Depreciation & Depletion & Amortization | $16.82M | $15.87M | $15.41M | $38.82M | $12.90M |
| Other Non-Cash Items | -$13.26M | -$234,000.00 | $20.93M | -$20.98M | -$22.19M |
| Change in Working Capital | -$14.01M | $10.19M | -$110.70M | -$47.88M | $91.11M |
| -Change in Receivables | $42,000.00 | -$19.73M | -$40.39M | -$10.15M | $22.21M |
| -Change in Inventory | -$18.12M | -$15.86M | $2.64M | -$53.90M | -$26.78M |
| -Change in Prepaid Assets | -$4.74M | $9.37M | -$408,000.00 | -$34.18M | -$21.81M |
| -Change in Payables and Accrued Expense | $10.69M | $37.50M | -$68.71M | $71.74M | $108.08M |
| -Change in Other Current Liabilities | -$2.70M | -$1.82M | -$2.31M | -$17.40M | $9.10M |
| -Change In Other Working Capital | $811,000.00 | $718,000.00 | -$1.52M | -$4.00M | $300,000.00 |
| Net cash flow from investing | -$442.41M | -$122.56M | -$93.74M | -$861.98M | $34.01M |
| Net Cash Flow from Continuing Investing Activities | -$442.41M | -$122.56M | -$93.74M | -$861.98M | $34.01M |
| Net PPE Purchase and Sale | -$2.66M | -$2.19M | -$1.20M | -$8.79M | -$2.37M |
| Net Intangibles Purchase and Sale | -$3.37M | -$4.95M | -$156,000.00 | -$291.15M | -$34.92M |
| Net Investment Purchase and Sale | -$436.39M | -$115.41M | -$92.38M | -$562.04M | $71.30M |
| Financing Cash Flow | -$73.24M | $211.88M | $6.40M | $331.09M | $302.50M |
| Net Cash Flow from Continuing Financing Activities | -$73.24M | $211.88M | $6.40M | $331.09M | $302.50M |
| Net Issuance Payments Of Debt | -$77.76M | – | – | -$1.61M | $0.00 |
| Proceeds from Stock Option Exercised | $5.35M | $16.40M | $6.40M | $99.05M | $62.50M |
| Net Other Financing Charges | -$822,000.00 | – | – | $233.66M | $240.00M |
| Ending Cash Balance | $525.34M | $1.07B | $850.44M | $998.33M | $998.33M |
| Net Change in Cash | -$540.96M | $218.44M | -$146.38M | $180.31M | $302.24M |
| Beginning Cash Balance | $1.07B | $850.44M | $998.33M | $795.32M | $686.30M |
| Effect of Exchange Rate Changes | -$38,000.00 | -$2.54M | -$1.52M | $22.71M | $9.80M |
| Free Cash Flow | -$31.33M | $121.97M | -$60.40M | $411.18M | -$71.56M |
| Deferred Tax | – | – | -$10,000.00 | -$3,000.00 | $1,000.00 |
No comments yet — be the first to weigh in on PTCT.
Sign in to join the discussion.